25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Adaptimmune Therapeutics PLC
Buy, Hold or Sell?

Let's analyze Adaptimmune Therapeutics PLC together

I guess you are interested in Adaptimmune Therapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Adaptimmune Therapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Adaptimmune Therapeutics PLC

I send you an email if I find something interesting about Adaptimmune Therapeutics PLC.

1. Quick Overview

1.1. Quick analysis of Adaptimmune Therapeutics PLC (30 sec.)










1.2. What can you expect buying and holding a share of Adaptimmune Therapeutics PLC? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.06
Expected worth in 1 year
€0.03
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
€-0.03
Return On Investment
-5.3%

For what price can you sell your share?

Current Price per Share
€0.56
Expected price per share
€0.525 - €0.775
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Adaptimmune Therapeutics PLC (5 min.)




Live pricePrice per Share (EOD)
€0.56

2.2. Growth of Adaptimmune Therapeutics PLC (5 min.)




Is Adaptimmune Therapeutics PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$96.2m$101.4m-$39.3m-63.4%

How much money is Adaptimmune Therapeutics PLC making?

Current yearPrevious yearGrowGrow %
Making money-$18.1m-$22.7m$4.6m25.6%
Net Profit Margin-5,541.6%-317.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Adaptimmune Therapeutics PLC (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Adaptimmune Therapeutics PLC?

Welcome investor! Adaptimmune Therapeutics PLC's management wants to use your money to grow the business. In return you get a share of Adaptimmune Therapeutics PLC.

First you should know what it really means to hold a share of Adaptimmune Therapeutics PLC. And how you can make/lose money.

Speculation

The Price per Share of Adaptimmune Therapeutics PLC is €0.56. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adaptimmune Therapeutics PLC.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adaptimmune Therapeutics PLC, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.06. Based on the TTM, the Book Value Change Per Share is €-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adaptimmune Therapeutics PLC.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.058.1%-0.01-2.5%-0.02-3.9%-0.03-4.9%-0.03-4.9%
Usd Book Value Change Per Share0.058.4%-0.01-1.4%-0.01-2.3%0.010.9%0.010.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.058.4%-0.01-1.4%-0.01-2.3%0.010.9%0.010.9%
Usd Price Per Share0.98-0.99-1.08-1.68-1.68-
Price to Earnings Ratio5.41--4.29-54.10-11.13-11.13-
Price-to-Total Gains Ratio20.95--35.39-180.92-33.67-33.67-
Price to Book Ratio15.64-36.91-11.77-20.99-20.99-
Price-to-Total Gains Ratio20.95--35.39-180.92-33.67-33.67-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.58772
Number of shares1701
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.01
Usd Total Gains Per Share-0.010.01
Gains per Quarter (1701 shares)-13.168.89
Gains per Year (1701 shares)-52.6235.58
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-53-6303626
20-105-11607162
30-158-169010798
40-210-2220142134
50-263-2750178170
60-316-3280213206
70-368-3810249242
80-421-4340285278
90-474-4870320314
100-526-5400356350

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.010.00.016.7%2.010.00.016.7%2.010.00.016.7%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%4.08.00.033.3%4.08.00.033.3%4.08.00.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%0.00.012.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%4.08.00.033.3%4.08.00.033.3%4.08.00.033.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Adaptimmune Therapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.045-0.007+117%-0.012+128%0.005+796%0.005+796%
Book Value Per Share--0.0600.041+46%0.090-33%0.107-44%0.107-44%
Current Ratio--3.0922.919+6%3.689-16%4.181-26%4.181-26%
Debt To Asset Ratio--0.7010.792-12%0.687+2%0.670+5%0.670+5%
Debt To Equity Ratio--2.3425.111-54%2.273+3%2.883-19%2.883-19%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--1219708466.3401166539490.520+5%885402111.585+38%1502610095.710-19%1502610095.710-19%
Eps--0.043-0.013+130%-0.021+148%-0.026+160%-0.026+160%
Ev To Ebitda Ratio--infinfnan%9.549+inf%infnan%infnan%
Ev To Sales Ratio--2.496216.715-99%26.623-91%214.980-99%214.980-99%
Free Cash Flow Per Share--0.029-0.008+129%-0.032+210%-0.016+154%-0.016+154%
Free Cash Flow To Equity Per Share--0.0440.000+161631%-0.031+171%-0.012+127%-0.012+127%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap--1434496264.7401383462275.520+4%1096552357.785+31%1715104583.910-16%1715104583.910-16%
Net Profit Margin--0.542-55.416+10321%-3.178+686%-26.595+5005%-26.595+5005%
Operating Margin----0%-0%-0%-0%
Operating Ratio--0.46458.585-99%5.270-91%28.884-98%28.884-98%
Pb Ratio9.366-67%15.63836.908-58%11.775+33%20.987-25%20.987-25%
Pe Ratio3.243-67%5.414-4.288+179%54.101-90%11.133-51%11.133-51%
Price Per Share0.560-67%0.9350.940-1%1.034-10%1.600-42%1.600-42%
Price To Free Cash Flow Ratio4.833-67%8.069-7.692+195%-62.827+879%-26.218+425%-26.218+425%
Price To Total Gains Ratio12.545-67%20.946-35.390+269%180.917-88%33.670-38%33.670-38%
Quick Ratio--0.0650.313-79%1.482-96%1.752-96%1.752-96%
Return On Assets--0.216-0.074+134%-0.068+132%-0.084+139%-0.084+139%
Return On Equity--0.722-0.749+204%-0.220+130%-0.405+156%-0.405+156%
Total Gains Per Share--0.045-0.007+117%-0.012+128%0.005+796%0.005+796%
Usd Book Value--96270495.62662070490.552+55%101431807.748-5%117165568.351-18%117165568.351-18%
Usd Book Value Change Per Share--0.047-0.008+117%-0.013+128%0.005+796%0.005+796%
Usd Book Value Per Share--0.0630.043+46%0.094-33%0.112-44%0.112-44%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--1280084035.4241224283195.301+5%929229516.108+38%1576989295.448-19%1576989295.448-19%
Usd Eps--0.045-0.014+130%-0.022+148%-0.027+160%-0.027+160%
Usd Free Cash Flow--46643302.122-11653075.813+125%-36146684.213+177%-18325832.915+139%-18325832.915+139%
Usd Free Cash Flow Per Share--0.030-0.009+129%-0.034+210%-0.016+154%-0.016+154%
Usd Free Cash Flow To Equity Per Share--0.0460.000+161631%-0.033+171%-0.012+127%-0.012+127%
Usd Market Cap--1505503829.8451451943658.158+4%1150831699.495+31%1800002260.814-16%1800002260.814-16%
Usd Price Per Share0.588-67%0.9810.987-1%1.085-10%1.679-42%1.679-42%
Usd Profit--69518469.436-18124340.250+126%-22755171.682+133%-28296303.310+141%-28296303.310+141%
Usd Revenue--128226332.39235363462.723+263%17690856.029+625%18662487.327+587%18662487.327+587%
Usd Total Gains Per Share--0.047-0.008+117%-0.013+128%0.005+796%0.005+796%
 EOD+4 -2MRQTTM+30 -5YOY+24 -125Y+21 -1410Y+21 -14

3.3 Fundamental Score

Let's check the fundamental score of Adaptimmune Therapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-153.243
Price to Book Ratio (EOD)Between0-19.366
Net Profit Margin (MRQ)Greater than00.542
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.065
Current Ratio (MRQ)Greater than13.092
Debt to Asset Ratio (MRQ)Less than10.701
Debt to Equity Ratio (MRQ)Less than12.342
Return on Equity (MRQ)Greater than0.150.722
Return on Assets (MRQ)Greater than0.050.216
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Adaptimmune Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.028
Ma 20Greater thanMa 500.618
Ma 50Greater thanMa 1000.675
Ma 100Greater thanMa 2000.816
OpenGreater thanClose0.550
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Adaptimmune Therapeutics PLC

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Adaptimmune Therapeutics PLC earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Adaptimmune Therapeutics PLC to the  industry mean.
  • A Net Profit Margin of 54.2% means that €0.54 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 54.2%. The company is making a huge profit. +2
  • The TTM is -5,541.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ54.2%TTM-5,541.6%+5,595.8%
TTM-5,541.6%YOY-317.8%-5,223.8%
TTM-5,541.6%5Y-2,659.5%-2,882.1%
5Y-2,659.5%10Y-2,659.5%0.0%
4.3.1.2. Return on Assets

Shows how efficient Adaptimmune Therapeutics PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Adaptimmune Therapeutics PLC to the  industry mean.
  • 21.6% Return on Assets means that Adaptimmune Therapeutics PLC generated €0.22 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 21.6%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is -7.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ21.6%TTM-7.4%+29.0%
TTM-7.4%YOY-6.8%-0.6%
TTM-7.4%5Y-8.4%+1.0%
5Y-8.4%10Y-8.4%0.0%
4.3.1.3. Return on Equity

Shows how efficient Adaptimmune Therapeutics PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Adaptimmune Therapeutics PLC to the  industry mean.
  • 72.2% Return on Equity means Adaptimmune Therapeutics PLC generated €0.72 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 72.2%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is -74.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ72.2%TTM-74.9%+147.2%
TTM-74.9%YOY-22.0%-53.0%
TTM-74.9%5Y-40.5%-34.4%
5Y-40.5%10Y-40.5%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Adaptimmune Therapeutics PLC.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Adaptimmune Therapeutics PLC is operating .

  • Measures how much profit Adaptimmune Therapeutics PLC makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Adaptimmune Therapeutics PLC to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient Adaptimmune Therapeutics PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 0.46 means that the operating costs are €0.46 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 0.464. The company is very efficient in keeping operating costs low. +2
  • The TTM is 58.585. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.464TTM58.585-58.120
TTM58.585YOY5.270+53.314
TTM58.5855Y28.884+29.700
5Y28.88410Y28.8840.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Adaptimmune Therapeutics PLC.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Adaptimmune Therapeutics PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 3.09 means the company has €3.09 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 3.092. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.919. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ3.092TTM2.919+0.173
TTM2.919YOY3.689-0.769
TTM2.9195Y4.181-1.262
5Y4.18110Y4.1810.000
4.4.3.2. Quick Ratio

Measures if Adaptimmune Therapeutics PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Adaptimmune Therapeutics PLC to the  industry mean.
  • A Quick Ratio of 0.06 means the company can pay off €0.06 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 0.065. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.313. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.065TTM0.313-0.248
TTM0.313YOY1.482-1.169
TTM0.3135Y1.752-1.439
5Y1.75210Y1.7520.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Adaptimmune Therapeutics PLC.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Adaptimmune Therapeutics PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Adaptimmune Therapeutics PLC to industry mean.
  • A Debt to Asset Ratio of 0.70 means that Adaptimmune Therapeutics PLC assets are financed with 70.1% credit (debt) and the remaining percentage (100% - 70.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 0.701. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.792. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.701TTM0.792-0.092
TTM0.792YOY0.687+0.105
TTM0.7925Y0.670+0.122
5Y0.67010Y0.6700.000
4.5.4.2. Debt to Equity Ratio

Measures if Adaptimmune Therapeutics PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Adaptimmune Therapeutics PLC to the  industry mean.
  • A Debt to Equity ratio of 234.2% means that company has €2.34 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adaptimmune Therapeutics PLC:

  • The MRQ is 2.342. The company is just not able to pay all its debts with equity.
  • The TTM is 5.111. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.342TTM5.111-2.770
TTM5.111YOY2.273+2.839
TTM5.1115Y2.883+2.229
5Y2.88310Y2.8830.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Adaptimmune Therapeutics PLC generates.

  • Above 15 is considered overpriced but always compare Adaptimmune Therapeutics PLC to the  industry mean.
  • A PE ratio of 5.41 means the investor is paying €5.41 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adaptimmune Therapeutics PLC:

  • The EOD is 3.243. Based on the earnings, the company is cheap. +2
  • The MRQ is 5.414. Based on the earnings, the company is cheap. +2
  • The TTM is -4.288. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD3.243MRQ5.414-2.171
MRQ5.414TTM-4.288+9.702
TTM-4.288YOY54.101-58.388
TTM-4.2885Y11.133-15.420
5Y11.13310Y11.1330.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adaptimmune Therapeutics PLC:

  • The EOD is 4.833. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 8.069. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -7.692. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD4.833MRQ8.069-3.236
MRQ8.069TTM-7.692+15.761
TTM-7.692YOY-62.827+55.134
TTM-7.6925Y-26.218+18.526
5Y-26.21810Y-26.2180.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Adaptimmune Therapeutics PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 15.64 means the investor is paying €15.64 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Adaptimmune Therapeutics PLC:

  • The EOD is 9.366. Based on the equity, the company is overpriced. -1
  • The MRQ is 15.638. Based on the equity, the company is expensive. -2
  • The TTM is 36.908. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD9.366MRQ15.638-6.272
MRQ15.638TTM36.908-21.270
TTM36.908YOY11.775+25.133
TTM36.9085Y20.987+15.921
5Y20.98710Y20.9870.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Income before Tax  -19,732-23,063-42,794-3,486-46,280568-45,712112,45366,741
Net Income  -20,379-23,069-43,449-2,207-45,655-558-46,214112,45366,240
Operating Income  -42,788-1,644-44,432-3,071-47,503567-46,936112,39365,457
Net Income from Continuing Operations  -20,379-23,069-43,449-2,207-45,655-558-46,214112,45366,240



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets321,702
Total Liabilities225,428
Total Stockholder Equity96,274
 As reported
Total Liabilities 225,428
Total Stockholder Equity+ 96,274
Total Assets = 321,702

Assets

Total Assets321,702
Total Current Assets253,770
Long-term Assets67,932
Total Current Assets
Cash And Cash Equivalents 211,810
Short-term Investments 2,979
Net Receivables 2,335
Other Current Assets 4,565
Total Current Assets  (as reported)253,770
Total Current Assets  (calculated)221,689
+/- 32,081
Long-term Assets
Property Plant Equipment 64,070
Intangible Assets 996
Long-term Assets Other 2,866
Long-term Assets  (as reported)67,932
Long-term Assets  (calculated)67,932
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities82,073
Long-term Liabilities143,355
Total Stockholder Equity96,274
Total Current Liabilities
Accounts payable 7,513
Other Current Liabilities 107
Total Current Liabilities  (as reported)82,073
Total Current Liabilities  (calculated)7,620
+/- 74,453
Long-term Liabilities
Long term Debt 24,954
Capital Lease Obligations Min Short Term Debt22,394
Long-term Liabilities Other 1,440
Long-term Liabilities  (as reported)143,355
Long-term Liabilities  (calculated)48,788
+/- 94,567
Total Stockholder Equity
Total Stockholder Equity (as reported)96,274
Total Stockholder Equity (calculated)0
+/- 96,274
Other
Capital Stock2,083
Common Stock Shares Outstanding 1,534,221
Net Invested Capital 121,228
Net Working Capital 171,697
Property Plant and Equipment Gross 130,897



6.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
353,528
469,545
419,799
388,270
332,202
328,916
288,081
342,984
296,638
282,616
258,010
321,702
321,702258,010282,616296,638342,984288,081328,916332,202388,270419,799469,545353,528
   > Total Current Assets 
300,450
415,458
359,461
321,165
264,139
255,370
213,748
261,771
219,368
207,552
186,903
253,770
253,770186,903207,552219,368261,771213,748255,370264,139321,165359,461415,458300,450
       Cash And Cash Equivalents 
42,918
149,948
89,539
97,811
79,001
108,033
119,866
76,969
90,059
143,991
140,670
211,810
211,810140,670143,99190,05976,969119,866108,03379,00197,81189,539149,94842,918
       Short-term Investments 
197,202
219,632
214,679
160,278
120,669
96,572
45,688
127,738
71,669
2,947
2,982
2,979
2,9792,9822,94771,669127,73845,68896,572120,669160,278214,679219,632197,202
       Net Receivables 
1,641
752
1,826
2,382
1,774
7,435
1,715
2,970
789
821
8,404
2,335
2,3358,4048217892,9701,7157,4351,7742,3821,8267521,641
       Inventory 
1,285
0
0
0
0
0
0
0
0
0
0
0
000000000001,285
       Other Current Assets 
5,273
2,828
2,278
3,201
2,883
3,206
2,974
3,099
2,973
3,741
4,505
4,565
4,5654,5053,7412,9733,0992,9743,2062,8833,2012,2782,8285,273
   > Long-term Assets 
53,078
54,087
60,338
67,105
68,063
73,546
74,333
81,213
77,270
75,064
71,107
67,932
67,93271,10775,06477,27081,21374,33373,54668,06367,10560,33854,08753,078
       Property Plant Equipment 
0
0
0
0
65,783
71,535
72,312
77,519
73,873
71,708
67,725
64,070
64,07067,72571,70873,87377,51972,31271,53565,7830000
       Intangible Assets 
1,191
1,000
788
612
568
442
443
463
384
330
524
996
9965243303844634434425686127881,0001,191
       Long-term Assets Other 
1,717
1,718
1,716
1,713
1,712
1,569
1,578
3,231
3,013
3,026
2,858
2,866
2,8662,8583,0263,0133,2311,5781,5691,7121,7131,7161,7181,717
> Total Liabilities 
112,545
263,585
256,654
246,353
218,865
247,038
204,205
216,333
208,509
243,103
233,635
225,428
225,428233,635243,103208,509216,333204,205247,038218,865246,353256,654263,585112,545
   > Total Current Liabilities 
41,137
62,541
66,151
73,632
66,080
64,501
63,631
76,125
75,146
72,788
66,411
82,073
82,07366,41172,78875,14676,12563,63164,50166,08073,63266,15162,54141,137
       Accounts payable 
4,784
8,113
7,017
15,991
6,905
4,753
5,187
14,713
13,922
8,128
6,587
7,513
7,5136,5878,12813,92214,7135,1874,7536,90515,9917,0178,1134,784
       Other Current Liabilities 
0
327
0
0
0
2,155
2,769
155
72
51
640
107
10764051721552,7692,1550003270
   > Long-term Liabilities 
71,408
201,044
190,503
172,721
152,785
182,537
140,574
140,208
133,363
170,315
167,224
143,355
143,355167,224170,315133,363140,208140,574182,537152,785172,721190,503201,04471,408
       Capital Lease Obligations Min Short Term Debt
25,971
25,468
25,955
24,192
22,400
23,077
22,833
26,342
25,601
25,235
23,692
22,394
22,39423,69225,23525,60126,34222,83323,07722,40024,19225,95525,46825,971
       Long-term Liabilities Other 
664
673
670
649
626
1,296
1,332
1,361
1,356
1,404
1,417
1,440
1,4401,4171,4041,3561,3611,3321,296626649670673664
> Total Stockholder Equity
240,983
205,960
163,145
141,917
113,337
81,878
83,876
126,651
88,129
39,513
24,375
96,274
96,27424,37539,51388,129126,65183,87681,878113,337141,917163,145205,960240,983
   Common Stock000000000000
   Retained Earnings Total Equity000000000000
   Accumulated Other Comprehensive Income 000000000000
   Capital Surplus 000000000000
   Treasury Stock000000000000
   Other Stockholders Equity 000000000000



6.4. Balance Sheets

Currency in USD. All numbers in thousands.




6.5. Cash Flows

Currency in USD. All numbers in thousands.




6.6. Income Statements

Currency in USD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue60,281
Cost of Revenue-0
Gross Profit060,281
 
Operating Income (+$)
Gross Profit0
Operating Expense-198,319
Operating Income-138,038-198,319
 
Operating Expense (+$)
Research Development126,509
Selling General Administrative71,810
Selling And Marketing Expenses0
Operating Expense198,319198,319
 
Net Interest Income (+$)
Interest Income5,964
Interest Expense-0
Other Finance Cost-0
Net Interest Income5,964
 
Pretax Income (+$)
Operating Income-138,038
Net Interest Income5,964
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-112,535-157,577
EBIT - interestExpense = 0
-113,871
-113,871
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-112,535
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-112,535
Tax Provision-1,336
Net Income From Continuing Ops-113,871-113,871
Net Income-113,871
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net19,539-5,964
 

Technical Analysis of Adaptimmune Therapeutics PLC
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Adaptimmune Therapeutics PLC. The general trend of Adaptimmune Therapeutics PLC is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Adaptimmune Therapeutics PLC's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Adaptimmune Therapeutics PLC.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.69 < 0.775 < 0.775.

The bearish price targets are: 0.545 > 0.535 > 0.525.

Tweet this
Adaptimmune Therapeutics PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Adaptimmune Therapeutics PLC. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Adaptimmune Therapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Adaptimmune Therapeutics PLC. The current macd is -0.03348666.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Adaptimmune Therapeutics PLC price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Adaptimmune Therapeutics PLC. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Adaptimmune Therapeutics PLC price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Adaptimmune Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartAdaptimmune Therapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Adaptimmune Therapeutics PLC. The current adx is 20.91.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Adaptimmune Therapeutics PLC shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Adaptimmune Therapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Adaptimmune Therapeutics PLC. The current sar is 0.681216.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Adaptimmune Therapeutics PLC Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Adaptimmune Therapeutics PLC. The current rsi is 36.03. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Adaptimmune Therapeutics PLC Daily Relative Strength Index (RSI) ChartAdaptimmune Therapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Adaptimmune Therapeutics PLC. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Adaptimmune Therapeutics PLC price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Adaptimmune Therapeutics PLC Daily Stochastic Oscillator ChartAdaptimmune Therapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Adaptimmune Therapeutics PLC. The current cci is -134.03508772.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Adaptimmune Therapeutics PLC Daily Commodity Channel Index (CCI) ChartAdaptimmune Therapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Adaptimmune Therapeutics PLC. The current cmo is -32.72256879.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Adaptimmune Therapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartAdaptimmune Therapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Adaptimmune Therapeutics PLC. The current willr is -86.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Adaptimmune Therapeutics PLC Daily Williams %R ChartAdaptimmune Therapeutics PLC Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Adaptimmune Therapeutics PLC. The current atr is 0.02988344.

Adaptimmune Therapeutics PLC Daily Average True Range (ATR) ChartAdaptimmune Therapeutics PLC Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Adaptimmune Therapeutics PLC. The current obv is 6,018.

Adaptimmune Therapeutics PLC Daily On-Balance Volume (OBV) ChartAdaptimmune Therapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Adaptimmune Therapeutics PLC. The current mfi is 68.44.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Adaptimmune Therapeutics PLC Daily Money Flow Index (MFI) ChartAdaptimmune Therapeutics PLC Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Adaptimmune Therapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-09-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-23ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-25STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-10-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-24ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Adaptimmune Therapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Adaptimmune Therapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.028
Ma 20Greater thanMa 500.618
Ma 50Greater thanMa 1000.675
Ma 100Greater thanMa 2000.816
OpenGreater thanClose0.550
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Adaptimmune Therapeutics PLC with someone you think should read this too:
  • Are you bullish or bearish on Adaptimmune Therapeutics PLC? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Adaptimmune Therapeutics PLC? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Adaptimmune Therapeutics PLC

I send you an email if I find something interesting about Adaptimmune Therapeutics PLC.


Comments

How you think about this?

Leave a comment

Stay informed about Adaptimmune Therapeutics PLC.

Receive notifications about Adaptimmune Therapeutics PLC in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.